Controlled transgene expression in regulatory t cells

Patent metadata

Field	Value
Publication number	US-12509703-B2
Application number	US-202016880402-A
Country	US
Kind code	B2
Filing date	May 21, 2020
Priority date	May 21, 2019
Publication date	Dec 30, 2025
Grant date	Dec 30, 2025

Abstract

The present disclosure provides mammalian cells such as regulatory T cells containing a transgene in the FOXP3 genomic locus. Also provided are methods of generating the cells and methods of using the cells to treat patients in need of immunosuppression.

First claim

What is claimed is:

1 . A genetically engineered, isolated mammalian cell comprising a heterologous sequence at an integration site in intron 4, 9, or 10 of a FOXP3 locus in the genome, wherein the heterologous sequence comprises
(i) a nucleotide sequence comprising contiguously all the FOXP3 exon sequences downstream of the integration site, (ii) a transgene, wherein the transgene is under the transcriptional control of the endogenous FOXP3 promoter in the FOXP3 locus; and (iii) a splice acceptor upstream of the nucleotide sequence to allow expression of a full-length FOXP3 mRNA transcript from the FOXP3 locus,
wherein the heterologous sequence is integrated such that when the promoter is activated, the cell expresses both FOXP3 protein and a product of the transgene from the locus, wherein the full-length FOXP3 mRNA is transcribed, under the transcriptional control of the endogenous FOXP3 promoter, from a combination of the endogenous FOXP3 exon sequences upstream of the integration site and the nucleotide sequence of (i), wherein the nucleotide sequence of (i) makes up for the downstream FOXP3 exon sequences that can no longer be expressed due to disruption at the gene locus.

2 . The cell of claim 1 , wherein the heterologous sequence comprises, between (i) and (ii), an internal ribosome entry site (IRES), or a coding sequence for a self-cleaving peptide in-frame with (i) and (ii).

3 . The cell of claim 2 , wherein the self-cleaving peptide is a 2A peptide, optionally selected from the group consisting of a P2A peptide, an E2A peptide, an F2A peptide, and a T2A peptide.

4 . The cell of claim 1 , wherein the transgene product is a chimeric antigen receptor (CAR) or a T-cell receptor (TCR).

5 . The cell of claim 4 , wherein the CAR or the TCR is specific for (i) an autoantigen, (ii) a B cell antigen optionally selected from CD19 and CD20, or (iii) an allogeneic HLA class I molecule, wherein the class I molecule is optionally HLA-A2.

6 . The cell of claim 1 , wherein the transgene product is a cytokine, a chemokine, a growth factor, or a signaling factor; or an AAV capsid protein selected from VP1, VP2, or VP3.

7 . The cell of claim 1 , wherein the cell is a lymphoid cell, a lymphoid progenitor cell, a mesenchymal stem cell, a hematopoietic stem cell, an induced pluripotent stem cell, or an embryonic stem cell.

8 . The cell of claim 7 , wherein the cell is a regulatory T (Treg) cell.

9 . The cell of claim 1 , wherein the cell comprises a null mutation in a gene selected from a T cell receptor alpha chain gene or a T cell receptor beta chain gene, a Class II major histocompatibility complex transactivator (CIITA) gene, an HLA Class I or II gene, a transporter associated with antigen processing, a minor histocompatibility antigen gene, and a ß2 microglobulin (B2M) gene.

10 . The cell of claim 1 , wherein the cell is a human cell.

11 . The cell of claim 1 , wherein the cell comprises a suicide gene optionally selected from a HSV-TK gene, a cytosine deaminase gene, a nitroreductase gene, a cytochrome P450 gene, or a caspase-9 gene.

12 . The cell of claim 1 , wherein the heterologous sequence is integrated at intron 4.

13 . The cell of claim 12 , wherein the transgene product is a CAR or a TCR.

14 . The cell of claim 13 , wherein the cell is a Treg cell.

15 . The cell of claim 1 , wherein the heterologous sequence is integrated at intron 9.

16 . The cell of claim 15 , wherein the transgene product is a CAR or a TCR.

17 . The cell of claim 16 , wherein the cell is a Treg cell.

18 . The cell of claim 1 , wherein the heterologous sequence is integrated at intron 10.

19 . The cell of claim 18 , wherein the transgene product is a CAR or a TCR.

20 . The cell of claim 19 , wherein the cell is a Treg cell.

21 . A method of making a genetically engineered mammalian cell, comprising:
(a) contacting an isolated mammalian cell with a nucleic acid construct comprising a heterologous sequence, wherein the heterologous sequence is flanked at the 5′ end with a first homology region for integration into intron 4, 9, or 10 of a FOXP3 locus in the genome and at the 3′ end with a second homology region for integration into intron 4, 9, or 10 of the FOXP3 locus, wherein the first and the second homology regions are both configured for integration into the same site in the FOXP3 locus, and wherein the heterologous sequence comprises (i) a nucleotide sequence comprising contiguously all the FOXP3 exon sequences downstream of the integration site, (ii) a transgene, wherein the transgene is under the transcriptional control of the endogenous FOXP3 promoter in the FOXP3 locus; and (iii) a splice acceptor upstream of the nucleotide sequence to allow expression of a full-length FOXP3 mRNA transcript from the FOXP3 locus, and (b) culturing the cell under conditions that allow the heterologous sequence to be integrated in intron 4, 9, or 10 of the FOXP3 locus such that when the promoter is activated, the cell expresses both FOXP3 protein and a product of the transgene from the locus, wherein the full-length FOXP3 mRNA is transcribed, under the transcriptional control of the endogenous FOXP3 promoter, from a combination of the endogenous FOXP3 exon sequences upstream of the integration site and the nucleotide sequence of (i), wherein the nucleotide sequence of (i) makes up for the downstream FOXP3 exon sequences that can no longer be expressed due to disruption at the gene locus.

22 . The method of claim 21 , wherein the heterologous sequence comprises, between (i) and (ii), an internal ribosome entry site (IRES), or a coding sequence for a self-cleaving peptide in-frame with (i) and (ii).

23 . The method of claim 21 , wherein the transgene product is a CAR or a TCR.

24 . The method of claim 23 , wherein the CAR or the TCR is specific for (i) an autoantigen, (ii) a B cell antigen optionally selected from CD19 and CD20, or (iii) an allogeneic HLA class I molecule, wherein the class I molecule is optionally HLA-A2.

25 . The method of claim 21 , wherein the cell comprises a null mutation in a gene selected from a T cell receptor alpha chain gene or a T cell receptor beta chain gene, a CIITA gene, an HLA Class I or II gene, a transporter associated with antigen processing, a minor histocompatibility antigen gene, and a ß2 microglobulin (B2M) gene.

Assignees

• Sangamo Therapeutics Inc

Inventors

• Conway Anthony

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/22

  Immunosuppressive or immunotolerising · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C12N5/0637 Primary

  Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg · CPC title